Compare Cassava Sciences Inc (FLNA) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs ProShares UltraPro S&P500 — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while ProShares UltraPro S&P500 trades at $145.59. The key difference: ProShares UltraPro S&P500 is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | UPRO | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $4.64 | $150.93 |
52-Week Low | $1.09 | $89.29 |
Enterprise Value | -$33.43M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
UPRO trades at $145.25, up 0.67% on the day, with a bullish technical signal driven by strong moving average alignment. The stock exhibits neutral oscillators but faces key resistance near $147. Recent news highlights S&P 500 momentum, with earnings season and inflation data influencing near-term direction.
The outlook remains cautiously optimistic given bullish technicals and positive market sentiment, though stretched valuations and macroeconomic risks pose headwinds. Investors should weigh strong institutional support against potential volatility from Fed policy and earnings results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
